Back to top
more

Blueprint Medicines (BPMC)

(Real Time Quote from BATS)

$92.54 USD

92.54
230,923

+0.25 (0.27%)

Updated Apr 24, 2024 02:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

CRISPR Therapeutics (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?

by Zacks Equity Research

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Moderna (MRNA) Soars 8.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Moderna (MRNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Here's What Key Metrics Tell Us About Blueprint Medicines (BPMC) Q4 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for Blueprint Medicines (BPMC) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Blueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines

by Zacks Equity Research

Blueprint (BPMC) climbs 14% on better-than-expected fourth-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion for the ISM indication.

Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 10.78% and 6.95%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Drug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More

by Zacks Equity Research

Let's look at five biotech/drug companies, ALNY, BPMC, AGIO, CORT and RARE, slated to release quarterly results on Feb 15.

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Clues to Blueprint Medicines (BPMC) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Blueprint Medicines (BPMC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex's (VRTX) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales numbers of its lead drug, Trikafta/Kaftrio, and progress with other pipeline candidates.

Gilead (GILD) Gears Up to Report Q4 Earnings: Whats in Store?

by Zacks Equity Research

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2023 results.

What Makes Blueprint Medicines (BPMC) a New Buy Stock

by Zacks Equity Research

Blueprint Medicines (BPMC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now

by Zacks Equity Research

Here, we discuss some reasons why investing in Blueprint (BPMC) stock now may turn out to be a more prudent move than ever.

Blueprint (BPMC) Gets EC Nod for Ayvakit Expanded Use, Stock Up

by Zacks Equity Research

Blueprint (BPMC) announces EC approval expanding Ayvakit's indication to include the treatment of adult patients with indolent systemic mastocytosis. The stock gained 5%.

Why Is Gilead (GILD) Up 1.9% Since Last Earnings Report?

by Zacks Equity Research

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Axsome (AXSM) Up 8.7% Since Last Earnings Report?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Glaxo (GSK) Up 5.3% Since Last Earnings Report?

by Zacks Equity Research

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Repligen (RGEN) Up 21.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 1.7% Since Last Earnings Report?

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.

How Much Upside is Left in Blueprint Medicines (BPMC)? Wall Street Analysts Think 42.16%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 42.2% in Blueprint Medicines (BPMC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Are Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year?

by Zacks Equity Research

Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.

Blueprint (BPMC) Stock Gains 26% on Q3 Earnings & Sales Beat

by Zacks Equity Research

Blueprint (BPMC) climbs 26% on better-than-expected third-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion in the United States.

Compared to Estimates, Blueprint Medicines (BPMC) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Blueprint Medicines (BPMC) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.